Viral-derived complement inhibitors: current status and potential role in immunomodulation

dc.contributor.authorAbou-El-Hassan, Hadi
dc.contributor.authorZaraket, Hassan
dc.contributor.departmentSpecialized Clinical Programs and Services
dc.contributor.departmentExperimental Pathology, Microbiology, and Immunology
dc.contributor.departmentCenter for Infectious Diseases Research
dc.contributor.facultyFaculty of Medicine (FM)
dc.contributor.institutionAmerican University of Beirut
dc.date.accessioned2025-01-24T12:20:18Z
dc.date.available2025-01-24T12:20:18Z
dc.date.issued2017
dc.description.abstractThe complement system is one of the body’s major innate immune defense mechanisms in vertebrates. Its function is to detect foreign bodies and promote their elimination through opsonisation or lysis. Complement proteins play an important role in the immunopathogenesis of several disorders. However, excessive complement activation does not confer more protection but instead leads to several autoimmune and inflammatory diseases. With inappropriate activation of the complement system, activated complement proteins and glycoproteins may damage both healthy and diseased tissues. Development of complement inhibitors represents an effective approach in controlling dysregulated complement activity and reducing disease severity, yet few studies have investigated the nature and role of novel complement inhibitory proteins of viral origin. Viral complement inhibitors have important implications in understanding the importance of complement inhibition and their role as a promising novel therapeutic approach in diseases caused by dysregulated complement function. In this review, we discuss the role and importance of complement inhibitors derived from several viruses in the scope of human inflammatory and autoimmune diseases. © 2016, © 2016 by the Society for Experimental Biology and Medicine.
dc.identifier.doihttps://doi.org/10.1177/1535370216675772
dc.identifier.eid2-s2.0-85011857448
dc.identifier.pmid27798122
dc.identifier.urihttp://hdl.handle.net/10938/34242
dc.language.isoen
dc.publisherSAGE Publications Inc.
dc.relation.ispartofExperimental Biology and Medicine
dc.sourceScopus
dc.subjectComplement
dc.subjectComplement inhibitor
dc.subjectComplement regulation
dc.subjectDisease
dc.subjectInflammation
dc.subjectVirus
dc.subjectAnimals
dc.subjectAutoimmune diseases
dc.subjectComplement activation
dc.subjectComplement inactivating agents
dc.subjectComplement system proteins
dc.subjectHumans
dc.subjectImmunomodulation
dc.subjectMice
dc.subjectViral proteins
dc.subjectVirus diseases
dc.subjectViruses
dc.subjectAntivirus agent
dc.subjectCoat protein
dc.subjectHepatitis b virus x protein
dc.subjectNonstructural protein 1
dc.subjectViral protein
dc.subjectArticle
dc.subjectAstrovirus infection
dc.subjectAtherosclerosis
dc.subjectAutoimmune disease
dc.subjectBlood transfusion
dc.subjectComplement system
dc.subjectDisease severity
dc.subjectFlaviviridae
dc.subjectHepatitis b virus
dc.subjectHerpes simplex virus 1
dc.subjectHuman
dc.subjectInflammatory disease
dc.subjectInnate immunity
dc.subjectMacular degeneration
dc.subjectMembranoproliferative glomerulonephritis
dc.subjectNeutrophil chemotaxis
dc.subjectNipah virus
dc.subjectNonhuman
dc.subjectOpsonization
dc.subjectPhagocytosis
dc.subjectPoxviridae
dc.subjectReperfusion injury
dc.subjectWest nile virus
dc.subjectAnimal
dc.subjectImmunology
dc.subjectMetabolism
dc.subjectMouse
dc.subjectVirus infection
dc.titleViral-derived complement inhibitors: current status and potential role in immunomodulation
dc.typeArticle

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
2017-9007.pdf
Size:
391.64 KB
Format:
Adobe Portable Document Format